CITIUS PHARMACEUTICALS INC (CTXR) Forecast, Price Target & Analyst Ratings

NASDAQ:CTXR • US17322U3068

Current stock price

0.8449 USD
-0.03 (-3.35%)
At close:
0.83 USD
-0.01 (-1.76%)
After Hours:

Analyst forecast overview

View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for CITIUS PHARMACEUTICALS INC (CTXR).

Forecast Snapshot

Consensus Price Target

Price Target
$5.10
+ 503.62% Upside
→ Price target details

Next Earnings Forecast

Earnings Estimate
Release Date
May 12, 2026
Period
Q2 / 2026
EPS Estimate
-$0.20
Revenue Estimate
10.068M
→ Full earnings forecast details

ChartMill Buy Consensus

Rating
80.00%
Weighted Analyst Rating Score
→ Analyst Ratings details

Price Target Details & History

Consensus Price Target and Range

Mean target
$5.10
Upside
+ 503.62%
From current price of $0.84 to mean target of $5.10, Based on 8 analyst forecasts
Low
$4.04
Median
$5.10
High
$6.30

Price Target Revisions

1 Month
0.00%
3 Months
0.00%

Price Target Summary

8 Wall Street analysts provided a forecast for the next 12 months for CTXR. The average price target is 5.1 USD. This implies a price increase of 503.62% is expected in the next year compared to the current price of 0.8449.
→ Find peer stocks trading 30% below analyst price target

Analyst Ratings & History

Current Analyst Ratings

CTXR Current Analyst RatingCTXR Current Analyst Buy, Sell and Hold Ratings.Current Analyst Rating Strong Buy Buy Hold Sell Strong Sell 0 0 0 0 0

Analyst Ratings History

CTXR Historical Analyst RatingsCTXR Historical Analyst Buy, Sell and Hold Ratings and number of analysts.Historical Monthly Analyst Rating -19 -17 -15 -13 -11 -9 -7 -5 -3 -1 2 4 6 8

Analyst Ratings Consensus

ChartMill Buy Consensus
80.00%
CTXR was analyzed by 8 analysts. The buy percentage consensus is at 80. So analysts seem to be have mildly positive about CTXR.
In the previous month the buy percentage consensus was at a similar level.
CTXR was analyzed by 8 analysts. More opinions would make the average more meaningful.
→ Find peer stocks with a buy consensus above 85%

Recent Upgrades & Downgrades

DateFirmActionFrom → To
2026-03-11D. Boral CapitalMaintains Buy -> Buy
2025-12-04D. Boral CapitalMaintains Buy -> Buy
2025-08-13D. Boral CapitalMaintains Buy -> Buy
2025-06-30D. Boral CapitalMaintains Buy -> Buy
2025-06-10D. Boral CapitalMaintains Buy -> Buy
2025-06-09D. Boral CapitalMaintains Buy -> Buy
2025-05-23Maxim GroupDowngrade Buy -> Hold
2025-05-15D. Boral CapitalMaintains Buy -> Buy
2025-02-18D. Boral CapitalMaintains Buy -> Buy
2025-01-07D. Boral CapitalMaintains Buy -> Buy
2024-12-30D. Boral CapitalUpgrade Hold -> Buy
2024-11-22D. Boral CapitalDowngrade Buy -> Hold
2024-11-12HC Wainwright & Co.Reiterate Buy -> Buy
2024-11-11D. Boral CapitalMaintains Buy -> Buy
2024-08-19EF HuttonMaintains Buy -> Buy
2024-08-08EF HuttonMaintains Buy -> Buy
2024-08-05EF HuttonMaintains Buy -> Buy
2024-07-15EF HuttonInitiate Buy
2024-05-31HC Wainwright & Co.Reiterate Buy -> Buy
2024-02-14HC Wainwright & Co.Reiterate Buy -> Buy
2023-08-10HC Wainwright & Co.Reiterate Buy -> Buy
2023-08-01HC Wainwright & Co.Maintains Buy -> Buy
2023-05-30HC Wainwright & Co.Reiterate Buy -> Buy
2023-04-03HC Wainwright & Co.Reiterate Buy
2023-03-29HC Wainwright & Co.Reiterate Buy

Next Earnings Forecast Details

Next Earnings Details

Release Date
May 12, 2026
Period
Q2 / 2026
EPS Estimate
-$0.20
Revenue Estimate
10.068M
Revenue Q2Q
N/A
EPS Q2Q
83.94%
Number of Analysts
3

Next Earnings Revisions

Revenue (1 Month)
0.00%
Revenue (3 Months)
0.00%
EPS (1 Month)
0.00%
EPS (3 Months)
0.00%

Next Earnings Summary

CTXR is expected to report earnings on 5/12/2026. The consensus EPS estimate for the next earnings is -0.2 USD and the consensus revenue estimate is 10.07M USD.
The next earnings revenue estimate has been revised downward by 0% in the past 3 months.
→ Find peers expecting at least 20% revenue growth next quarter

Full Analyst Estimates 2026 - 2033

Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates

2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033
Revenue
YoY % growth
CTXR revenue by date.CTXR revenue by date.
N/AN/A
147.57%		N/A
50.28%		N/A
21.50%		N/A
14.50%		N/A
13.35%		N/A
-31.28%		N/A
5.57%
EBITDA
YoY % growth
CTXR ebitda by date.CTXR ebitda by date.
N/A-7.45M-9.99M
-34.09%		-13.79M
-38.04%		-15.6M
-13.13%		-17.71M
-13.53%		-23.54M
-32.92%		-33.32M
-41.55%		-36.729M
-10.23%		-41.994M
-14.33%		N/AN/AN/AN/AN/AN/AN/AN/AN/A
EBIT
YoY % growth
CTXR ebit by date.CTXR ebit by date.
-3.23M-7.45M
-130.65%		-9.99M
-34.09%		-13.79M
-38.04%		-15.6M
-13.13%		-17.71M
-13.53%		-23.54M
-32.92%		-33.32M
-41.55%		-36.732M
-10.24%		-41.996M
-14.33%		-38.526M
8.26%		N/A
143.59%		N/A
464.71%		N/A
58.60%		N/A
26.58%		N/A
17.21%		N/A
15.57%		N/A
-28.49%		N/A
6.58%
Operating Margin
CTXR operating margin by date.CTXR operating margin by date.
N/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
EPS
YoY % growth
CTXR eps by date.CTXR eps by date.
N/AN/AN/AN/A-0.78
98.05%		-11.50
-1,374.36%		-6.75
41.30%		-5.50
18.52%		N/A
25.82%		-5.84
-43.19%		-4.09
29.99%		N/A
141.40%		N/A
68.07%		N/A
-11.11%		N/A
14.11%		N/A
4.59%		N/A
8.78%		N/A
3.73%		N/A
3.59%

All data in USD

Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates

Q2 / 26 Q3 / 26 Q4 / 26 Q1 / 27 Q2 / 27 Q3 / 27 Q4 / 27
EPS
Q2Q % growth		-0.20
83.94%		-0.01
98.73%		-0.37
49.00%		0.33
3,300.00%		0.34
265.00%		0.37
3,700.00%		0.38
202.78%
Revenue
Q2Q % growth		10.068M15.102M18.667M41.071M
941.33%		42.856M
325.67%		46.428M
207.43%		48.213M
158.28%
EBITDA
Q2Q % growth		N/AN/AN/AN/AN/AN/AN/A
EBIT
Q2Q % growth		-4.649M
58.71%		-1.891M
78.48%		-558.96K
93.38%		17.498M
294.01%		18.259M
492.74%		19.781M
1,146.02%		20.541M
3,774.86%

All data in USD

Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data

CTXR Yearly Revenue VS EstimatesCTXR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2025 2026 2027 2028 2029 2030 2031 2032 2033 100M 200M 300M
CTXR Yearly EPS VS EstimatesCTXR Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 -10 -20 -30 -40

Long Term Forward Growth Forecast Summary

Long Term EPS Growth (CAGR)

EPS Next 3 Year
37.83%
EPS Next 5 Year
22.32%

Long Term Revenue Growth (CAGR)

Revenue Next 3 Year
213.93%
Revenue Next 5 Year
112.22%

Long Term EBIT Growth (CAGR)

EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A
→ Find peers expecting at least 20% CAGR revenue growth over the next 3 years

CITIUS PHARMACEUTICALS INC / CTXR Forecast FAQ

Can you provide the average price target for CITIUS PHARMACEUTICALS INC stock?

8 analysts have analysed CTXR and the average price target is 5.1 USD. This implies a price increase of 503.62% is expected in the next year compared to the current price of 0.8449.

When does CITIUS PHARMACEUTICALS INC (CTXR) report earnings?

CITIUS PHARMACEUTICALS INC (CTXR) will report earnings on 2026-05-12.

What are the consensus estimates for CTXR stock next earnings?

The consensus EPS estimate for the next earnings of CITIUS PHARMACEUTICALS INC (CTXR) is -0.2 USD and the consensus revenue estimate is 10.07M USD.

How many analysts cover CITIUS PHARMACEUTICALS INC (CTXR) stock?

The number of analysts covering CITIUS PHARMACEUTICALS INC (CTXR) is 8.